Overview: LPL Expert Panel 4 TestIntroduction: The LPL Expert Panel 4 Test reviews histopathology of 20+ blocks to diagnose cancer, causing swelling or pain. Following 2023 CAP guidelines, it uses histopathology for high specificity, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in histopathology for patients with suspected extensive malignancies.
Other Names: LPL Panel 4 Assay, Cancer Histopathology Review (20+ Blocks).
FDA Status: Laboratory-developed test (LDT), meeting histopathology standards for diagnostic accuracy.
Historical Milestone: Expert histopathology panels expanded in the 1990s with cancer diagnostics. Multi-block reviews improved in the 2000s, enhancing diagnostic precision.
Purpose: Reviews histopathology of 20+ blocks to diagnose cancer, guides treatment, and evaluates patients with swelling or pain.
Test Parameters: 1. Histopathology Review (20+ Blocks)
Pretest Condition: No fasting required. Collect tissue. Report history of swelling, pain, or cancer symptoms.
Specimen: Tissue (FFPE, 0.5-2 cma³). Transport in a biohazard container.
Sample Stability at Room Temperature: 7 days
Sample Stability at Refrigeration: Not refrigerated
Sample Stability at Frozen: Not frozen
Medical History: Document swelling, pain, weight loss, or family history of cancer. Include current medications, especially chemotherapy.
Consent: Written consent required, detailing the tests purpose, cancer implications, and risks of biopsy.
Procedural Considerations: Uses histopathology to review 20+ tissue blocks. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for extensive cancer diagnosis.
Factors Affecting Result Accuracy: Improper tissue fixation or low tissue quality can affect results. Insufficient block number may limit diagnosis.
Clinical Significance: Abnormal histopathology confirms cancer, guiding treatment (e.g., surgery, chemotherapy). Normal results may require further testing.
Specialist Consultation: Consult an oncologist or pathologist for result interpretation and treatment planning.
Additional Supporting Tests: Immunohistochemistry, molecular profiling, or imaging (e.g., PET-CT) to confirm cancer diagnosis.
Test Limitations: Extensive block review increases complexity; clinical correlation is needed. Invasive biopsy carries risks.
References: CAP Pathology Guidelines, 2023; Archives of Pathology, Fitzgibbons PL, 2022.
